BioCentury | Jan 3, 2019
Distillery Therapeutics

Neurology

...a heat-inactivated version of the peptide did not. In vitro , the FMR1 peptide bound KCNN2...
...the peptide on neurological deficits in the model. TARGET/MARKER/PATHWAY: Fragile X mental retardation 1 (FMR1); potassium channel KCa2.2 (KCNN2)...
...Mo. email: klyachko@wustl.edu Claire Quang Washington University School of Medicine in St. Louis Fragile X mental retardation 1 (FMR1) Potassium channel KCa2.2 (KCNN2) Fragile...
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...and Ataxion Inc., gaining lead product, CAD-1883, from the latter. The positive allosteric modulator of potassium channel KCa2.2 (KCNN2)...
...board. Cadent Therapeutics Inc., Cambridge, Mass. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics Inc. Disrupted in schizophrenia 1 (DISC1) NMDA receptor Potassium channel KCa2.2 (KCNN2) Potassium...
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...and Ataxion Inc., gaining lead product, CAD-1883, from the latter. The positive allosteric modulator of potassium channel KCa2.2 (KCNN2)...
...and Access Industries joined Cadent's board. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics Inc. Disrupted in schizophrenia 1 (DISC1) NMDA receptor Potassium channel KCa2.2 (KCNN2) Potassium...
BioCentury | Aug 31, 2018
Company News

Urovant gets rights to gene therapy for overactive bladder

Ion Channel Innovations LLC (Ardsley, N.Y.) granted Urovant Sciences Ltd. (Basel, Switzerland) rights to develop and commercialize hMaxi-K, a gene therapy in development for overactive bladder. Next year, Urovant plans to start a Phase II...
BioCentury | Aug 28, 2018
Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof....
BioCentury | Jun 28, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 124 genomic loci could help predict the risk of myopia and other ocular refractive errors. Genome-wide association studies (GWAS) in 255,925 individuals identified associations between ocular refractive errors including myopia and...
BioCentury | May 24, 2018
Translation in Brief

Channel for T cell invasion

University of Cincinnati researchers have found that increasing potassium flux through the KCa3.1 channel could boost CD8 + T cell migration into the tumor microenvironment, raising the prospect that this could present a new mechanism...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
BioCentury | Sep 29, 2017
Financial News

SpringWorks launches with $103M series A

On Sept. 25, SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed....
Items per page:
1 - 10 of 33